Neuropsychological effects of treatments for adults with cancer: A meta-analysis and review of the literature

Journal of the International Neuropsychological Society

Volumn 9, Issue 7, 2003, Pages 967-982

  Anderson Hanley, Cay ^a   Sherman, Marne L ^b   Riggs, Raine ^c   Agocha, V Bede ^d   Compas, Bruce E ^e  

^a SKIDMORE COLLEGE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c BROWN UNIVERSITY   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

^e VANDERBILT UNIVERSITY   (United States)

Author keywords

Cancer; Chemotherapy; Executive function; Meta analysis; Motor function; Verbal memory

Indexed keywords

ADULT; CANCER THERAPY; COGNITION; COGNITIVE DEFECT; DATA ANALYSIS; DISEASE SEVERITY; HUMAN; INTERMETHOD COMPARISON; MEDICAL LITERATURE; MEDICAL RESEARCH; MENTAL FUNCTION; META ANALYSIS; MOTOR PERFORMANCE; NEUROPSYCHOLOGY; PRIORITY JOURNAL; REVIEW; SAMPLING; STATISTICAL SIGNIFICANCE; VERBAL MEMORY;

EID: 0242643519     PISSN: 13556177     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1355617703970019     Document Type: Review

References (83)

1. Ahles, T.A. & Saykin, A.J. (2001). Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Investigator, 19, 812-820.
2. Ahles, T.A., Saykin, A.J., Furstenberb, C.T., Cole, B., Mott, L.A., Skalla, K., Whedon, M.B., Bivens, S., Mitchell, T., Greenberg, R., & Silberfarb, P.M. (2002). Neuropsychological impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. Journal of Clinical Oncology, 20, 485-493.
3. Ahles, T.A., Silberfarb, P.M., Rundle, A.C., Holland, J.C., Kornblith, A.B., Canellos, G.P., Green, M.R., & Perry, M.C. (1994). Psychotherapy Psychosomatics, 62, 193-199.
4. Ahles, T.A., Tope, D.M., Furstenberg, C., Hann, D., & Mills, L. (1996). Psychologic and neuropsychologic impact of autologous bone marrow transplantation. Journal of Clinical Oncology, 14, 1457-1462.
5. Andrykowski, M.A., Schmitt, F.A., Gregg, M.E., Brady, M.J., Lamb, D.G., & Henlsee-Downey, P.J. (1992). Neuropsychological impairment in adult bone marrow transplant candidates. Cancer, 70, 2288-2297.
6. Archibald, Y., Lunn, D., Ruttan, L., Macdonald, D., Del Maestro, R., Barr, H., Pexman, W., Fisher, B., Gaspar, L., & Cairncross, G. (1994). Cognitive functioning in long-term survivors of highgrade glioma. Journal of Neurosurgery, 80, 247-253.
7. Bender, C.M., Paraska, K.K., Sereika, S.M., Ryan, C.M., & Berga, S.L. (2001). Cognitive Function and Reproductive Hormones in Adjuvant Therapy for Breast Cancer: A Critical Review. Journal of Pain and Symptom Management, 21, 407-424.
8. Bonadonna, G., Valagussa, V.E., & Rossi, A. (1985). Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Research and Treatment, 5, 95.
9. Borenstein, M. & Rothstein, H. (2002). Comprehensive Meta Analysis Computer Program and Manual. Englewood Cliffs, NJ: Biostat, Inc.
10. Brezden, C.B., Phillips, K., Abdolell, M., Bunston, T., & Tannock, I.F. (2000). Cognitive function in breast cancer patients receiving adjuvant chemotherapy. Journal of Clinical Oncology, 18, 2695-2701.
11. Brundage, M.D. (1997). Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. Journal of Clinical Oncology, 15, 330-340.
12. Butler, R.W. (2002). Attentional processes and their remediation in children treated for cancer: a literature review and the development of a therapeutic approach. Journal of the International Neuropsychological Society, 8, 115-124.
13. Capuron, L., Ravaud, A., & Dantzer, R. (2001). Timing and specificity of the cognitive changes induced by Interleukin-2 and Interferon-α treatments in cancer patients. Psychosomatic Medicine, 63, 376-386.
14. Caraceni, A., Martini, C., Belli, F., Macheroni, L., Rivoltini, L., Arienti, F., & Cascinelli, N. (1992). Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administration. European Journal of Cancer, 29A, 1266-1269.
15. Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ: Lawrence Erlbaum Associates.
16. Cooper, H. & Hedges, L.V. (1994). Handbook of research synthesis. New York: Russell Sage Foundation.
17. Copeland, D.R., Fletcher, J.M., & Pfefferbaum-Levine, B. (1985). Neuropsychological sequelae of childhood cancer in long-term survivors. Pediatrics, 75, 745-753.
18. Cull, A., Gregor, A., Hopwood, P., Macbeth, F., Karnicka-Mlodkowska, H., Thatcher, N., Burt, P., Stepniewska, K., & Stewart, M. ( 1994). Neurological and cognitive impairment in long-term survivors of small cell lung cancer. European Journal of Cancer, 30a, 1067-1074.
19. Cull, A., Hay, C., Love, S.B., Mackie, M., Smets, E., & Stewart, M. (1996). What do cancer patients mean when they complain of concentration and memory problems? British Journal of Cancer, 74, 1674-1679.
20. Daly, E., Komaroff, A.L., Bloomingdale, K., Wilson, S., & Albert, M.S. (2001). Neuropsychological function in patients with chronic fatigue syndrome, multiple sclerosis, and depression. Applied Neuropsychology, 8, 12-22.
21. Denicoff, K.D., Rubinow, D.R., Papa, M.Z., Simpson, C., Seipp, C.A., Lotze, M.T., Change, A.E., Rosenstein, D., & Rosenberg, S.A. (1987). The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Annals of Internal Medicine, 107, 293-300.
22. Devlen, J., Maguire, P., Phillips, P., & Crowther, D. (1987a). Psychological problems associated with diagnosis and treatment of lymphomas: II. Prospective study. British Journal of Medicine, 295, 955-957.
23. Devlen, J., Maguire, P., Phillips, P., Crowther, D., & Chambers, H. (1987b). Psychological problems associated with diagnosis and treatment of lymphomas. I: Retrospective study. British Journal of Medicine, 295, 953-954.
24. Dikinen, S.S., Heaton, R.K., Grant, I., & Temkin, N.R. (1999). Test-retest reliability and practice effects of Expanded Halstead-Reitan Neuropsychological Test Battery. Journal of the International Neuropsychological Society, 5, 346-356.
25. Eiser, C.J. (1998). Practitioner review: Long-term consequences of childhood cancer. Child Psychology and Psychiatry, 39, 621-633.
26. Ferguson, R.J. & Ahles, T.A. (2002). Brief cognitive-behavioral treatment of chemotherapy-associated attention and memory complaints among breast cancer survivors: Pilot data. Poster presented at the Annual Meeting of the Society of Behavioral Medicine, Washington, DC.
27. Fisher, B., Costantino, J.P., & Redmond, C.K. (1994). Endometrial cancer in tamoxifen-treated breas, cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. Journal of the National Cancer Institute, 86, 527.
28. Fleishman, S.B. & Kalash, G.R. (1998). Chemotherapeutic agents and neuropsychiatric side effects. In J.C. Holland (Ed.), Psychooncology (pp. 630-658). New York: Oxford University Press.
29. Ganz, P.A. (1998). Cognitive dysfunction following adjuvant treatment of breast cancer: A new dose-limiting toxic effect? Journal of the National Cancer Institute, 90, 182-183.
30. Gotay, C.C. (1987). Quality of life among survivors of childhood cancer: A critical review and implications for intervention. Journal of Psychosocial Oncology, 5, 5-23.
31. Harder, H., Cornelissen, J.J., Van Gool, A.R., Duivenvoorden, H.J., Eijkenboom, W.M., & van den Bent, M.J. (2002). Cognitive functioning and quality of life in long-term adult survivors of bone marrow transplantation. Cancer, 95, 183-192.
32. Kaasa, S., Olsnes, B.T., & Mastekaasa, A. (1988a). Neuropsychological evaluation of patients with inoperable non-small cell lung cancer treated with combination chemotherapy or radiotherapy. Acta Oncologica, 27, 241-246.
33. Kaasa, S., Olsnes, B.T., Thorud, E., & Host, H. (1988b). Reduced short-term neuropsychological performance in patients with nonsmall-cell lung cancer treated with cisplatin and etoposide. Antibiotics and Chemotherapy, 41, 226-231.
34. Komaki, R., Meyers, C.A., Dong, M.S., Garden, A.S., Byrne, K., Nickens, J.A., & Cox, J.D. (1995). Evaluation of cognitive function in patients with small cell lung cancer prior to and shortly following prophylactic cranial irradiation. International Journal of Radiation Oncology, Biology, and Physiology, 33, 179-182.
35. Mann, D. (1999). Memory lock: Is chemobrain making you forgetful? MAMM: Women, Cancer and Community, December/January, 67-69.
36. Mayerhofer, K., Bodner-Adler, B., Bodner, K., Saletu, B., Schindl, M., Kaider, A., Hefler, L., Leodolter, S., & Kainz, C. (2000). A Paclitaxel-containing chemotherapy does not cause central nervous adverse effects: A prospective study in patients with ovarian cancer. Anticancer Research, 20, 4051-4056.
37. McCaffrey, R.J., Duff, K., & Westervelt, H.J. (2000). Practitioner's guide to evaluating change with intellectual assessment instruments. New York: Kluwer Academic.
38. Meyers, C.A. (2000). Neurocognitive dysfunction in cancer patients. Oncology, 14, 75-79.
39. Meyers, C.A. (2001). Mental status changes associated with biotherapy. In P.T. Rieger (Ed.), Biotherapy: A comprehensive overview (2nd ed., pp. 605-621). Boston: Jones and Bartlett Publishers.
40. Meyers, C.A. & Abbruzzese, J.L. (1992). Cognitive functioning in cancer patients: Effect of previous treatment. Neurology, 42, 434-436.
41. Meyers, C.A., Byrne, K., & Komaki, R. (1995). Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer, 12, 231-235.
42. Meyers, C.A. & Scheibel, R.S. (1990). Early detection and diagnosis of neurobehavioral disorders associated with cancer and its treatment. Oncology, 4, 115-122.
43. Meyers, C.A., Weitzner, M., Byrne, K., Valentine, A., Champlin, R.E., & Przepiorka, D. (1994). Evaluation of the neurobehavioral functioning of patients before, during and after bone marrow transplantation. Journal of Clinical Oncology, 12, 820-826.
44. National Cancer Institute (1998). Surveillance, Epidemiology, and End Results (SEER) Program public-use data (1973-1998), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2001, based on the August 2000 submission. Bethesda, MD: Author.
45. Olin, J.J. (2001). Cognitive function after systemic therapy for breast cancer. Oncology, 15, 613-624.
46. Oxman, T.E. & Silberfarb, P.M. (1980). Serial cognitive testing in cancer patients receiving chemotherapy. American Journal of Psychiatry, 137, 1263-1265.
47. Paganini-Hill, A. & Clark, L.J. (2000). Preliminary assessment of cognitive function in breast cancer patients treated with Tamoxifen. Breast Cancer Research and Treatment, 64, 165-176.
48. Parth, P., Dunlap, W.P., Kennedy, R.S., Ordy, J.M., & Lane, N.E. (1989). Motor and cognitive testing of bone marrow transplant patients after chemoradiotherapy. Perceptual Motor Skills, 68, 1227-1241.
49. Pavol, M.A., Meyers, C.A., Rexer, J.L., Valentine, A.D., Mattis, P.J., & Talpaz, M. (1995). Pattern of neurobehavioral deficits associated with interferon-alfa therapy for leukemia. Neurology, 45, 947-950.
50. Peace, K., Freeman, J., Perez, D., & Tripp, G. (2002). Long-term effects of adjuvant chemotherapy on cognitive functioning in patients with breast or bowel cancer: Preliminary findings. Poster presented at the Annual Meeting of the International Neuropsychological Society; Stockholm, Sweden.
51. Peterson, L.G. & Popkin, M.K. (1980). Neuropsychiatric effects of chemotherapeutic agents for cancer. Psychosomatics, 21, 141-153.
52. Petros, W.P. (2002). Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. Clinical Cancer Research, 8, 698-705.
53. Piper, B.F. (1998). The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. Oncology Nursing Forum, 25, 677-684.
54. Redd, W.H., Silberfarb, P.M., Anderson, B.L., Andrykowski, M.A., Bovbjerg, D.H., Burish, T.G., Carpenter, P.J., Cleeland, C., Dolgin, M., & Levy, S.M. (1991). Physiological and psychobehavioral research in oncology. Cancer, 67(suppl.), 813-822.
55. Riggs, R., Sherman, M., Muss, H., Anderson-Hanley, C., O'Brien, P., & Compas, B. (May, 2001). A Prospective Study of the Neuropsychological Effects of Systemic Treatments for Early Stage Breast Cancer. Abstract published in the Proceedings of the American Society for Clinical Oncology, 20, 29b.
56. Roman, D.D. & Sperduto, P.W. (1995). Neuropsychological effects of cranial radiation: Current knowledge and future directions. International Journal of Radiation Oncology, Biology and Physics, 31, 983-998.
57. Rosenthal, R. (1991). Meta-analytic procedures for social research (Rev. ed.). Newbury Park, CA: Sage.
58. Rosenthal, R. & DiMatteo, M.R. (2001). Meta-Analysis: Recent developments in quantitative methods for literature reviews. Annual Review of Psychology, 52, 59-82.
59. Salinsky, M.C., Storzbach, D., Dodrill, C.B., & Binder, L.M. (2001). Test-retest bias, reliability, and regression equations for neuropsychological measures repeated over a 12-16-week period. Journal of the International Neuropsychological Society, 7, 597-605.
60. Saphner, T., Tormey, D.C., & Gray, R. (1991). Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. Journal of Clinical Oncology, 9, 286-294.
61. Schagen, S.B., van Dam, S.B., Muller, M.J., Boogerd, W., Lindeboom, J., & Bruning, P.F. (1999). Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer, 85, 640-650.
62. Shadish, W.R. & Haddock, C.K. (1994). Combining estimates of effect size. In H. Cooper & L.V. Hedges, (Eds.), Handbook of Research Synthesis, (pp. 261-281). New York: Russell Sage Foundation.
63. Silberfarb, P.M. (1983). Chemotherapy and cognitive defects in cancer patients. Annual Review of Medicine, 34, 35-46.
64. Silberfarb, P.M. & Oxman, T.E. (1988). The effects of cancer therapies on the central nervous system. Advances in Psychosomatic Medicine, 18, 13-25.
65. Silberfarb, P.M., Philibert, D., & Levine, P.M. (1980). Psychosocial aspects of neoplastic disease, II: Affective and cognitive effects of chemotherapy in cancer patients. American Journal of Psychiatry, 137, 597-601.
66. Temkin, N.R., Heaton, R.K., Grant, I., & Dikmen, S.S. (1999). Detecting significant change in neuropsychological test performance: A comparison of four models. Journal of International Neuropsychological Society, 5, 357-369.
67. Tiersky, L.A., Johnson, S.K., Lange, G., Natelson, B.H., & DeLuca, J. (1997). Neuropsychology of chronic fatigue syndrome: A critical review. Journal of Clinical and Experimental Neuropsychology, 19, 560-586.
68. Tope, D.M., Ahles, T.A., & Silberfarb, P.M. (1993). Psycho-oncology: Psychological well-being as one component of quality of life. Psychotherapy Psychosomatics, 60, 129-147.
69. Trask, P.C., Esper, P., Riba, M., & Redman, B. (2000). Psychiatric side effects of interferon therapy: Prevalence, proposed mechanisms, and future directions. Journal of Clinical Oncology, 18, 2316-2326.
70. Troy, L., McFarland, K., Littman-Power, S., Kelly, B.J., Walpole, E.T., Wyld, D., & Thompson, D. (2000). Cisplatin-based therapy: A neurological and neuropsychological review. Psycho-Oncology, 9, 29-39.
71. Tucker, J., Prior, P.F., Green, C.R., Ede, G.M., Stevenson, J.F., Gawler, J., Jamal, G.A., Charlesworth, M., Thakkar, C.M., Patel. P., & Lister, T.A. (1989). Minimal neuropsychological sequelae following prophylactic treatment of the central nervous system in adult leukemia and lymphoma. British Journal Cancer, 60, 775-780.
72. van Dam, F.S.A.M., Schagen, S.B., Muller, M.J., Boogerd, W., Wall, E., Fortuyn, M.E.D., & Rodenhuis, S. (1998). Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. Journal of the National Cancer Institute, 90, 210-218.
73. van Oosterhout, A.G., Ganzevles, P.G., Wilmink, J.T., De Geus, B.W., Van Vonderen, R.G., & Twijnstra, A. (1996). Sequelae in long-term survivors of small cell lung cancer. International Journal of Oncology, Biology and Physics, 34, 1037-1044.
74. Videtic, G.M. (2001). Using treatment interruptions to palliate the toxicity from concurrent chemoradiation for limited small cell lung cancer decreases survival and disease control. Lung Cancer, 33, 249-258.
75. Walch, S.E., Ahles, T.A., & Saykin, A.J. (1998). Neuropsychological impact of cancer and cancer treatments. In J.C. Holland (Ed.), Psycho-oncology, (pp. 500-508). New York: Oxford University Press.
76. Walker, L.G., Walker, M.B., Heys, S.D., Lolley, J., Wesnes, K., & Eremin, O. (1997). The psychological and psychiatric effects of rIL-2 therapy: A controlled clinical trial. Psychooncology, 6, 290-301.
77. Walker, L.G., Wesnes, K.P., Heys, S.D., Walker, M.B., Lolley, J., & Eremin, O. (1996). The cognitive effects of recombinant Interleukin-2 (rIL-2) therapy: A controlled clinical trial using computerized assessments. European Journal of Cancer, 32A, 2275-2283.
78. Weiss, H.D., Walker, M.D., & Wiernik, P.H. (1974a). Neurotoxicity of commonly used antineoplastic agents (first of two parts). New England Journal of Medicine, 291, 75-81.
79. Weiss, H.D., Walker, M.D., & Wiernik, P.H. (1974b). Neurotoxicity of commonly used antineoplastic agents (second of two parts). New England Journal of Medicine, 291, 127-133.
80. Weitzner, M.A. & Meyers, C.A. (1997). Cognitive functioning and quality of life in malignant glioma patients: A review of the literature. Psycho-Oncology, 6, 169-177.
81. Weitzner, M.A., Meyers, C.A., & Valentine, A.D. (1995). Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment. Journal of Neuropsychiatry and Clinical Neurosciences, 7, 347-350.
82. Wiencke, M.H. & Dienst, E.R. (1995). Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology, 4, 61-66.
83. Yaffe, K., Krueger, K., Sarkar, S., Grady, D., Barrett-Connor, E., Cox, D.A., & Nickelsen, T. (2001). Cognitive function in post-menopausal women treated with Raloxifene. New England Journal of Medicine, 344, 1207-1213.